Publicaciones en las que colabora con Óscar Lorenzo González (23)

2023

  1. A Pilot Study: The Reduction in Fecal Acetate in Obese Patients after Probiotic Administration and Percutaneous Electrical Neurostimulation

    Nutrients, Vol. 15, Núm. 5

2021

  1. Mcp-1 predicts recurrent cardiovascular events in patients with persistent inflammation

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-13

2020

  1. Addition of probiotics to anti-obesity therapy by percutaneous electrical stimulation of dermatome T6. A pilot study

    International Journal of Environmental Research and Public Health, Vol. 17, Núm. 19, pp. 1-14

2018

  1. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: Role of GLP-1 isoforms in Glut4 receptor trafficking

    Cardiovascular Diabetology, Vol. 17, Núm. 1

2017

  1. Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway

    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 10, pp. 207-222

2015

  1. Targeting metabolic disturbance in the diabetic heart

    Cardiovascular Diabetology, Vol. 14, Núm. 1

  2. Updating experimental models of diabetic cardiomyopathy

    Journal of Diabetes Research, Vol. 2015

2014

  1. Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1842, Núm. 2, pp. 293-303

2013

  1. Alteration of energy substrates and ROS production in diabetic cardiomyopathy

    Mediators of Inflammation, Vol. 2013

  2. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes

    Cardiovascular Diabetology, Vol. 12, Núm. 1

  3. Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

    PLoS ONE, Vol. 8, Núm. 10

2012

  1. Proteome changes in the myocardium of experimental chronic diabetes and hypertension. Role of PPARα in the associated hypertrophy

    Journal of Proteomics, Vol. 75, Núm. 6, pp. 1816-1829

2011

  1. Potential role of nuclear factor κb in diabetic cardiomyopathy

    Mediators of Inflammation, Vol. 2011

2009

  1. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes

    American Journal of Physiology - Heart and Circulatory Physiology, Vol. 297, Núm. 6

2005

  1. Angiotensin IV activates the nuclear transcription factor-κB and related proinflammatory genes in vascular smooth muscle cells

    Circulation Research, Vol. 96, Núm. 9, pp. 965-973

2004

  1. Angiotensin II, via AT1 and AT2 receptors and NF-κB pathway, regulates the inflammatory response in unilateral ureteral obstruction

    Journal of the American Society of Nephrology, Vol. 15, Núm. 6, pp. 1514-1529

2003

  1. Angiotensin II Increases Connective Tissue Growth Factor in the Kidney

    American Journal of Pathology, Vol. 163, Núm. 5, pp. 1937-1947

  2. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis

    Circulation, Vol. 108, Núm. 12, pp. 1499-1505

  3. Inflammation and angiotensin II

    International Journal of Biochemistry and Cell Biology, Vol. 35, Núm. 6, pp. 881-900

2002

  1. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney

    Kidney International, Supplement, Vol. 62, Núm. 82, pp. S12-S22